Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR0945)
Drug Name
Levomilnacipran
Synonyms
Levomilnacipran; Levomilnacipran (USAN/INN); Levomilnacipran [USAN:INN]; Milnacipram; SB17447; SCHEMBL1414867; UGM0326TXX; ZINC506; (+)-Milnacipran; Fetzima; GJJFMKBJSRMPLA-DZGCQCFKSA-N; (1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide; (1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide; (1S,2R)-milnacipran; 96847-54-0; 96847-55-1; AC1OCEN8; BDBM50032379; CHEBI:136040; CHEMBL99946; D10072; DB08918; F 2695; F-2695; GTPL7435; UNII-UGM0326TXX; f2-695
Indication Depression [ICD11: 6A71] Approved [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 246.35 Topological Polar Surface Area 46.3
Heavy Atom Count 18 Rotatable Bond Count 5
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 2
Cross-matching ID
PubChem CID
6917779
PubChem SID
16010452 ; 23950786 ; 43529203 ; 50872352 ; 103316413 ; 103940908 ; 114786948 ; 127962304 ; 135626792 ; 137129347 ; 139020085 ; 160658357 ; 175271225 ; 175427154 ; 178104007 ; 179149463 ; 198967714 ; 227628532 ; 250148599
ChEBI ID
CHEBI:136040
CAS Number
96847-55-1
TTD Drug ID
D02XOK
Formula
C15H22N2O
Canonical SMILES
CCN(CC)C(=O)C1(CC1CN)C2=CC=CC=C2
InChI
1S/C15H22N2O/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12/h5-9,13H,3-4,10-11,16H2,1-2H3/t13-,15+/m0/s1
InChIKey
GJJFMKBJSRMPLA-DZGCQCFKSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
Levomilnacipran glucuronide DM000305 N. A. Conjugation - Glucuronidation 1 [4]
N-desethyl LVM DM000301 N. A. Oxidation - Desmethylation 1 [2]
p-hydroxy-levomilnacipran DM000303 N. A. Oxidation - Hydroxylation 1 [2]
Desethyl levomilnacipran glucuronide DM000302 N. A. Conjugation - Glucuronidation 2 [2]
p-hydroxy levomilnacipran glucuronide DM000304 N. A. Conjugation - Glucuronidation 2 [2]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR001505 Levomilnacipran N-desethyl LVM Oxidation - Desmethylation CYP3A4 ... [2]
MR001506 Levomilnacipran p-hydroxy-levomilnacipran Oxidation - Hydroxylation Unclear [2]
MR001507 Levomilnacipran Levomilnacipran glucuronide Conjugation - Glucuronidation Unclear [4]
MR001503 N-desethyl LVM Desethyl levomilnacipran glucuronide Conjugation - Glucuronidation Unclear [2]
MR001504 p-hydroxy-levomilnacipran p-hydroxy levomilnacipran glucuronide Conjugation - Glucuronidation Unclear [2]
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 2C8 (CYP2C8) DME0018 Homo sapiens
CP2C8_HUMAN
1.14.14.1
[2]
Cytochrome P450 2D6 (CYP2D6) DME0009 Homo sapiens
CP2D6_HUMAN
1.14.14.1
[3]
Cytochrome P450 2J2 (CYP2J2) DME0031 Homo sapiens
CP2J2_HUMAN
1.14.14.24
[3]
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[3]
Mephenytoin 4-hydroxylase (CYP2C19) DME0021 Homo sapiens
CP2CJ_HUMAN
1.14.14.1
[3]
References
1 Levomilnacipran was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
2 The role of levomilnacipran in the management of major depressive disorder: a comprehensive review. Curr Neuropharmacol. 2016;14(2):191-9.
3 The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review Curr Neuropharmacol. 2016;14(2):191-9. doi: 10.2174/1570159x14666151117122458.
4 LABEL:EVOMILNACIPRAN capsule, extended release

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.